الفهرس 
Plasma level of MiRNA-499 as an early biomarker in patients with acute decompensated heart failure
AbstractOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Background: MiRNAs (miRNAs) are endogenous small RNAs that are 21{u2013}25 nucleotides in length. Recently, plasma miRNAs have been reported to be sensitive and specific biomarkers of various tissue injuries and cardiovascular conditions. MiRNA-499 is a newly discovered member of the miRNAs, and is mainly expressed in the myocardium. The circulating miRNAs value has been extensively addressed in patients with acute coronary syndrome. However, prognostic performances of miRNAs in patients with acute decompensated heart failure (ADHF) has received less attention. Objectives: The purpose of this study is to identify the potential relationship between early plasma levels of miRNA-499, within the first 24 hours after hospital admission, and early plasma level of brain natriuretic peptide (BNP) in hospitalized patients with acute decompensated heart failure and its relation to the clinical outcomes. Patients and methods: A total 30 patients with acute decompensated heart failure were recruited in our study. Blood samples were collected within the first 24 hours of admission to the intensive care unit. The plasma concentrations of well-characterized miRNA (miRNA-499) was assessed by a real-time reverse transcription-polymerase chain reaction (PCR Test) for all patients using artificial small RNA (Cell-miRNA39) as an internal reference gene. The level of miRNA-499 expression was measured using the cycle threshold